US Patent

US10188652 — Compositions and methods for treating insomnia

Method of Use · Assigned to Eisai R&D Management Co Ltd · Expires 2035-10-21 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions and methods for treating insomnia using a specific compound as an orexin receptor antagonist.

USPTO Abstract

In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.

Drugs covered by this patent

Dayvigo (LEMBOREXANT) · Eisai

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2791`	—	Dayvigo
`U-2791`	—	Dayvigo

Patent Metadata

Patent number: US10188652
Jurisdiction: US
Classification: Method of Use
Expires: 2035-10-21
Drug substance claim: No
Drug product claim: Yes
Assignee: Eisai R&D Management Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.